XCancer

A Multicentre, Prospective, Open-label Study With [68Ga]Ga-ABY-025 PET-imaging to Characterize HER2-expression and Explore the Therapy-predictive Value for HER2-antibody Drug Conjugates in Patients With Metastatic Breast Cancer

Description:

This is a prospective, multi-center, open-label, exploratory diagnostic phase II imaging trial for patients with metastatic breast cancer with at least one line of systemic therapy.

Sponsor:

Henske Altena

Phase:

N/A

Contacts:

Renske Altena, MD, PHD

renske.altena@ki.se

Thuy Tran, Associate Prof, PharmD, PhD (Associate Professor)

thuy.tran@regionstockholm.se

+46812377777

Government Study Link:

NCT06830382 - Click here to see study on

ClinicalTrials.gov

[68Ga]Ga-ABY-025

Isotope(s):
Target(s):
  • HER2